BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA New data on atopic dermatitis and prurigo nodularis New data ... frown lines and crow’s feet, as well as from the phase ...

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) ...

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year ...

Orthoscan, Inc., proudly announces the launch of VERSA, a groundbreaking mini C-arm for clinical imaging, debuting at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in San Diego, ...

Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the ...

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ruxolitinib cream 1.5% in adults with prurigo nodularis (PN). The data ...